Decheng Capital Leads $30M Series C Round In China’s Impact Therapeutics

Chinese investment firm Decheng Capital has led a US$30 million series C round in Nanjing-based pharmaceutical firm Impact Therapeutics.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY